Supernus, Inc.
INDV- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001625297
In the last 90 days, Supernus, Inc. insiders filed 1 open-market purchase and 0 sales; 340 institutions reported holding it in 13F filings for Q2 2026, worth $4.98B in total; Oaktree Capital is the only superinvestor holding it.
Other share classesSUPN
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Oct 30, 2026, 1:19 AM ET
Revenue flow, FY2025
Where the revenue went in FY2025, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 |
| Filing | 10-K | 10-K | 20-F |
| Reported | Feb 26, 2026 | – | – |
| Revenue | $1.24B | $1.19B | $1.09B |
| Cost of revenue | $246.0M | $231.0M | $186.0M |
| Gross profit | $994.0M | $957.0M | $907.0M |
| Operating expenses | – | $925.0M | – |
| Research and development | $97.0M | $107.0M | $106.0M |
| Selling, general and administrative | $634.0M | $618.0M | $811.0M |
| Operating income | $262.0M | $32.0M | -$4.00M |
| Interest expense | $38.0M | $32.0M | $38.0M |
| Income tax | $29.0M | $11.0M | -$1.00M |
| Net income | $210.0M | $2.00M | $2.00M |
| EPS, basic | $1.68 | $0.02 | – |
| EPS, diluted | $1.64 | $0.02 | – |
| Weighted shares, basic | 125.0M | 132.0M | 137.3M |
| Weighted shares, diluted | 128.0M | 133.0M | 141.8M |
| Margins and growth | |||
| Gross margin | 80.2% | 80.6% | 83.0% |
| Operating margin | 21.1% | 2.7% | -0.4% |
| Net margin | 16.9% | 0.2% | 0.2% |
| Revenue growth, year over year | +4.3% | +8.7% | – |
| Net income growth, year over year | +10,400.0% | 0.0% | – |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 |
| Filing | 10-K | 10-K | 20-F |
| Reported | Feb 26, 2026 | – | – |
| Cash and equivalents | $195.0M | $319.0M | $316.0M |
| Short-term investments | $0 | $1.00M | $10.0M |
| Accounts receivable | $253.0M | $254.0M | $254.0M |
| Inventory | $153.0M | $178.0M | $142.0M |
| Total current assets | $652.0M | $839.0M | $1.26B |
| Property, plant and equipment | $144.0M | $100.0M | $84.0M |
| Goodwill | $2.00M | $2.00M | – |
| Intangible assets | – | – | $237.0M |
| Total assets | $1.20B | $1.32B | $1.95B |
| Accounts payable | $48.0M | $63.0M | $743.0M |
| Short-term debt | $29.0M | $18.0M | $3.00M |
| Total current liabilities | $914.0M | $939.0M | $1.30B |
| Long-term debt | $290.0M | $315.0M | $236.0M |
| Total liabilities | $1.30B | $1.67B | $1.95B |
| Shareholders' equity | -$98.0M | -$348.0M | $0 |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 |
| Filing | 10-K | 10-K | 20-F |
| Reported | Feb 26, 2026 | – | – |
| Operating cash flow | -$27.0M | $36.0M | -$315.0M |
| Capital expenditures | $66.0M | $29.0M | $8.00M |
| Free cash flow | -$93.0M | $7.00M | -$323.0M |
| Depreciation and amortization | $10.0M | $29.0M | – |
| Stock-based compensation | $26.0M | $24.0M | $22.0M |
| Share buybacks | $11.0M | $173.0M | $33.0M |
| Investing cash flow | -$66.0M | $69.0M | -$98.0M |
| Financing cash flow | -$30.0M | -$102.0M | -$46.0M |
| Net change in cash | – | – | -$458.0M |
| Ratio | |||
| Stock-based compensation, % of revenue | 2.1% | 2.0% | 2.0% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.